Banque Cantonale Vaudoise’s Alaunos Therapeutics TCRT Stock Holding History

Banque Cantonale Vaudoise’s Portfolio TCRT Stock Details TCRT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-55	Closed	-$4K	–	1210
2023 Q2	$4K	Hold	55	–	–	﹤0.01%	1143
2023 Q1	$5K	Hold	55	–	–	﹤0.01%	1143
2022 Q4	$5K	Hold	55	–	–	﹤0.01%	1146
2022 Q3	$14K	Sell	55 -1	-2%	-$290	﹤0.01%	1129
2022 Q2	$10K	Buy	56 +1	+2%	+$96	﹤0.01%	1185
2022 Q1	$5K	Sell	55 -97	-64%	-$12.4K	﹤0.01%	1249
2021 Q4	$25K	Sell	152 -11	-7%	-$2.42K	﹤0.01%	1165
2021 Q3	$45K	Sell	163 -6	-4%	-$1.83K	﹤0.01%	1064
2021 Q2	$67K	Hold	169	–	–	﹤0.01%	1017
2021 Q1	$91K	Sell	169 -3	-2%	-$1.87K	﹤0.01%	928
2020 Q4	$65K	Sell	172 -4	-2%	-$1.59K	﹤0.01%	908
2020 Q3	$67K	Hold	176	–	–	﹤0.01%	881
2020 Q2	$87K	Sell	176 -6	-3%	-$2.67K	0.01%	798
2020 Q1	$67K	Sell	182 -3	-2%	-$1.55K	0.01%	812
2019 Q4	$131K	Buy	+185	New	+$127K	0.01%	780

Other funds holding TCRT

DCM

Discovery Capital Management South Norwalk, Connecticut $1.92B AUM 218.96% 1-Year Est. Return

MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Commerce Bank Kansas City, Missouri $20.7B AUM 23.76% 1-Year Est. Return

Banque Cantonale Vaudoise's TCRT Position: Q3 2023 in Review

Banque Cantonale Vaudoise sold out of Alaunos Therapeutics (TCRT) in Q3 2023, closing a stake of 55 shares — an estimated $4K sold.

Banque Cantonale Vaudoise first reported a position in TCRT in Q4 2019 and held it in 15 quarters. The position peaked at $131K in Q4 2019. 89 funds tracked by Wall St. Rank hold TCRT as of Q3 2023.

Banque Cantonale Vaudoise reported no remaining Alaunos Therapeutics position as of Q3 2023 after selling out during the quarter.
Banque Cantonale Vaudoise sold 55 Alaunos Therapeutics shares in Q3 2023, an estimated $4K.
Banque Cantonale Vaudoise first reported a position in Alaunos Therapeutics in Q4 2019 and held it in 15 quarters.
Banque Cantonale Vaudoise's Alaunos Therapeutics position peaked at $131K in Q4 2019.
89 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q3 2023.

Based on Banque Cantonale Vaudoise's 13F filing for Q3 2023, filed 8 Nov 2023.